Organon, Shanghai Henlius Say EU Approves Denosumab Biosimilars
MT Newswires Live
Sep 19
Organon (OGN) and partner Shanghai Henlius Biotech said Friday the European Commission granted marketing authorization for the Bildyos and Bilprevda injections, denosumab biosimilars to Prolia and Xgeva.
The approvals cover all indications of the reference products, including treatment of osteoporosis and prevention of skeletal-related events in certain cancer patients, the companies said.
Under a 2022 agreement, Organon holds exclusive rights to commercialize Bildyos and Bilprevda outside China.
Prolia and Xgeva are trademarks registered in Europe by Amgen (AMGN).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.